DareonTM-5: An open-label phase 2 trial of BI 764532, a DLL3-targeting T-cell engager, in patients (pts) with relapsed/refractory small cell lung cancer or other neuroendocrine carcinomas

被引：1
|
作者：
Gambardella, Valentina
Greystoke, Alastair
Reck, Martin
Liu, Meiruo
Mueller, Martha
Duenzinger, Ulrich
Bergsland, Emily B.
Owonikoko, Taofeek
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT279
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT279
引用
收藏
页数：2
相关论文
共 50 条
  • [1] DareonTM-5: An open-label Phase II trial of BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory small cell lung cancer or other neuroendocrine carcinomas
    Gambardella, Valentina
    Greystoke, Alastair
    Reck, Martin
    Liu, Meiruo
    Mueller, Martha
    Duenzinger, Ulrich
    Bergsland, Emily B.
    Owonikoko, Taofeek
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [2] Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas
    Wermke, Martin
    Felip, Enriqueta
    Gambardella, Valentina
    Kuboki, Yasutoshi
    Morgensztern, Daniel
    Hamed, Zohra Oum'
    Liu, Meiruo
    Studeny, Matus
    Owonikoko, Taofeek K.
    FUTURE ONCOLOGY, 2022, 18 (24) : 2639 - 2649
  • [3] Phase I trial of the DLL3/CD3 IgG-like T cell engager BI 764532 in patients (pts) with DLL3-positive (+) tumours: Focus on neuroendocrine carcinomas
    Gambardella, V.
    Castillon, J. Capdevila
    Kuboki, Y.
    Alese, O.
    Morgensztern, D.
    Sayehli, C. M.
    Sanmamed, M. F.
    Arriola, E.
    Hamed, Z. Oum'
    Song, E.
    Studeny, M.
    Wermke, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S499 - S500
  • [4] A phase I, open-label, dose-escalation trial of BI 764532, a DLL3/CD3 bispecific antibody, in patients (pts) with small cell lung carcinoma (SCLC) or other neuroendocrine neoplasms expressing DLL3.
    Wermke, Martin
    Felip, Enriqueta
    Gambardella, Valentina
    Kuboki, Yasutoshi
    Morgensztern, Daniel
    Hamed, Zohra Oum'
    Geng, Junxian
    Studeny, Matus
    Owonikoko, Taofeek K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] Randomized phase 3 study of tarlatamab, a DLL3-targeting bispecific T-cell engager (BiTE), compared to standard of care in patients with relapsed small cell lung cancer (DeLLphi-304).
    Paz-Ares, Luis G.
    Felip, Enriqueta
    Ahn, Myung-Ju
    Blackhall, Fiona Helen
    Borghaei, Hossein
    Cho, Byoung Chul
    Johnson, Melissa Lynne
    Ramalingam, Suresh S.
    Reck, Martin
    Zhang, Alicia
    Ju, Chia-Hsin
    Minocha, Mukul
    Mukherjee, Sujoy
    Suri, Gaurav
    Jandial, Danielle
    Bebb, D. Gwyn
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Phase 2 study of tarlatamab, a DLL3-targeting, half life-extended, bispecific T-cell engager (HLE BiTE) immuno-oncology therapy, in relapsed/refractory small cell lung cancer (SCLC).
    Ramalingam, Suresh S.
    Ahn, Myung-Ju
    Akamatsu, Hiroaki
    Blackhall, Fiona Helen
    Borghaei, Hossein
    Hummel, Horst-Dieter
    Johnson, Melissa Lynne
    Reck, Martin
    Zhang, Yiran
    Jandial, Danielle
    Cheng, Sunfa
    Paz-Ares, Luis G.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] DAREON™-7: A phase 1, open-label, dose escalation and expansion cohort trial of the delta-like ligand (DLL3)-targeting T-cell engager BI 764532, plus first-line platinum-based chemotherapy in patients with DLL3-positive (+) neuroendocrine carcinomas
    Capdevila, Jaume
    Vandamme, Timon
    Niccoli, Patricia
    Mishima, Saori
    Kato, Ken
    Ma, Yiyuan
    Sun, Ping
    Geng, Lijiang
    Lauer, Ulrich M.
    CANCER RESEARCH, 2024, 84 (07)
  • [8] Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) plus ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3
    Mazieres, J.
    Duruisseaux, M.
    Curcio, H.
    Morizane, C.
    Galot, R.
    Rottey, S.
    Stratmann, J. A.
    Ma, Y.
    Bouzaggou, M.
    Geng, L.
    Wermke, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1076 - S1077
  • [9] Updated data from a phase I trial of the DLL3/CD3 IgG-like T-cell engager BI 764532 in patients (pts) with DLL3-positive (+) tumors: Focus on extrapulmonary neuroendocrine carcinomas (epNECs)
    Capdevila, J.
    Gambardella, V
    Kuboki, Y.
    Alese, O. B.
    Morgensztern, D.
    Sayehli, C.
    Sanmamed, M. F.
    Arriola, E.
    Wolf, J.
    Owonikoko, T.
    Studeny, M.
    Wermke, M.
    JOURNAL OF NEUROENDOCRINOLOGY, 2024, 36 : 227 - 227
  • [10] Randomized Phase-3 Study: Tarlatamab, a DLL3-targeting Bispecific T-cell engager (BiTE), Compared to Standard-of-Care in Relapsed Small Cell Lung Cancer (DeLLphi-304)
    Rodriguez, Luis Paz -Ares
    Felip, Enriqueta
    Ahn, Myung-Ju
    Blackhall, Fiona Helen
    Borghaei, Hossein
    Cho, Byoung Chul
    Johnson, Melissa Lynne
    Ramalingam, Suresh S.
    Reck, Martin
    Jiang, Tony
    Ju, Chia-Hsin
    Minocha, Mukul
    Mukherjee, Sujoy
    Suri, Gaurav
    Recondo, Gonzalo
    Martinezi, Pablo
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E34 - E34
12345